|
Name |
1,1,3,3,5,5,7,7,9,9,11,11,13,13-Tetradecamethylheptasiloxane
|
| Molecular Formula | C14H42O6Si7 | |
| IUPAC Name* |
NA
|
|
| SMILES |
C[Si](C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)C
|
|
| InChI |
InChI=1S/C14H42O6Si7/c1-21(2)15-23(5,6)17-25(9,10)19-27(13,14)20-26(11,12)18-24(7,8)16-22(3)4/h1-14H3
|
|
| InChIKey |
JJIDUNHDYJESJA-UHFFFAOYSA-N
|
|
| Synonyms |
19095-23-9; 1,1,3,3,5,5,7,7,9,9,11,11,13,13-Tetradecamethylheptasiloxane; Heptasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13-tetradecamethyl-; AC1LB8OT; SCHEMBL9004474; DTXSID70339091; MFCD30721597; T3548; 1,1,3,3,5,5,7,7,9,9,11,11,13,13-tetradecamethyl-h eptasiloxane; 1,1,3,3,5,5,7,7,9,9,11,11,13,13-Tetradecamethylheptasiloxane #; 2,4,4,6,6,8,8,10,10,12,12,14-dodecamethyl-3,5,7,9,11,13-hexaoxa-2,4,6,8,10,12,14-heptasilapentadecane
|
|
| CAS | 19095-23-9 | |
| PubChem CID | 6329088 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 503.07 | ALogp: | 5.1 |
| HBD: | 0 | HBA: | 6 |
| Rotatable Bonds: | 12 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 55.4 | Aromatic Rings: | 0 |
| Heavy Atoms: | 27 | QED Weighted: | 0.332 |
| Caco-2 Permeability: | -5.824 | MDCK Permeability: | 0.00006060 |
| Pgp-inhibitor: | 0.096 | Pgp-substrate: | 0.757 |
| Human Intestinal Absorption (HIA): | 0.991 | 20% Bioavailability (F20%): | 0.014 |
| 30% Bioavailability (F30%): | 0.009 |
| Blood-Brain-Barrier Penetration (BBB): | 0 | Plasma Protein Binding (PPB): | 111.82% |
| Volume Distribution (VD): | 3.45 | Fu: | 18.88% |
| CYP1A2-inhibitor: | 0.234 | CYP1A2-substrate: | 0.971 |
| CYP2C19-inhibitor: | 0.853 | CYP2C19-substrate: | 0.97 |
| CYP2C9-inhibitor: | 0.863 | CYP2C9-substrate: | 0.963 |
| CYP2D6-inhibitor: | 0.026 | CYP2D6-substrate: | 0.936 |
| CYP3A4-inhibitor: | 0.515 | CYP3A4-substrate: | 0.094 |
| Clearance (CL): | 2.544 | Half-life (T1/2): | 0.322 |
| hERG Blockers: | 0.453 | Human Hepatotoxicity (H-HT): | 0.004 |
| Drug-inuced Liver Injury (DILI): | 0.014 | AMES Toxicity: | 0.028 |
| Rat Oral Acute Toxicity: | 0 | Maximum Recommended Daily Dose: | 0.215 |
| Skin Sensitization: | 0.771 | Carcinogencity: | 0.022 |
| Eye Corrosion: | 1 | Eye Irritation: | 0.998 |
| Respiratory Toxicity: | 0.032 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001783 | ![]() |
0.870 | D06IGU | ![]() |
0.101 | ||
| ENC001785 | ![]() |
0.851 | D0H2DQ | ![]() |
0.099 | ||
| ENC000373 | ![]() |
0.586 | D0Z1ZM | ![]() |
0.097 | ||
| ENC000530 | ![]() |
0.422 | D06ZUP | ![]() |
0.094 | ||
| ENC001271 | ![]() |
0.364 | D03HJK | ![]() |
0.091 | ||
| ENC003080 | ![]() |
0.320 | D02YIZ | ![]() |
0.087 | ||
| ENC001404 | ![]() |
0.261 | D04JMQ | ![]() |
0.086 | ||
| ENC003081 | ![]() |
0.257 | D06EEL | ![]() |
0.084 | ||
| ENC001122 | ![]() |
0.247 | D0L2UN | ![]() |
0.080 | ||
| ENC001182 | ![]() |
0.245 | D07DIM | ![]() |
0.079 | ||